Advanced Ovarian Cancer
Conditions
Interventions
Experiment group:Nab-paclitaxel plus Carboplatin
Control group:Solvent paclitaxel plus Carboplatin
Sponsors
Liaoning Cancer Hospital & Institute, Cancer Hospital of China Medical University
Eligibility
Sex/Gender
Female
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) Female, 18 to 75 years old; 2) Stage II-IV ovarian epithelial cancer, fallopian tube cancer, and primary peritoneal cancer confirmed by histopathology; 3) Receiving primary tumor cytoreductive surgery to achieve R0 or R1 within 6 weeks before enrollment; 4) Have not received chemotherapy before; 5) ECOG = 3 months; 7) Bone marrow function: white blood cells >= 3 x 10^9 / L, neutrophils >= 1.5 x10^9 / L, platelets >= 100 x 10^9 / L, hemoglobin >= 90g / L; 8) Liver and kidney function: total bilirubin (TBIL) <= 1.5 times the upper limit of normal value, alanine aminotransferase (ALT), aspartate aminotransferase (AST) are <= 2.5 times the upper limit of normal value; if due to liver metastasis, the above indicators <= 5 times the upper limit of normal value; serum creatinine (Cr) <= 1.5 times the upper limit of normal value; 9) Non-lactating women; 10) Sign written informed consent before trial.
Exclusion criteria
Exclusion criteria: 1) Have received other anti-tumor treatments (such as radiotherapy and immunotherapy) within 1 month before starting treatment; 2) With central nervous system disease or brain metastasis; 3) Occurred peripheral neuropathy of degree II or above; 4) Uncontrolled serious diseases will affect the ability to receive treatment : such as severe heart disease, cerebrovascular disease, uncontrolled diabetes, uncontrolled hypertension, uncontrolled infection, active digestibility ulcers 5) History of other malignant tumors within 5 years(except cured skin basal cancer and cervical cancer) ; 6) Alergic or intolerant to the study-related drug or its excipients; 7) Participating in other clinical trials at the same time; 8) The investigator judges the subjects who are not suitable to participate in this study. 9)Patients who are willing to undergo maintenance therapy on the premise that the investigator informs them that maintenance therapy is available after the study treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival;adverse events; | — |
Countries
China
Contacts
Public ContactDanbo Wang
Liaoning Cancer Hospital & Institute, Cancer Hospital of China Medical University
Outcome results
None listed